Intermountain INSPIRE Registry

Condition Clinical Trial

Official title:

INtermountain Healthcare Biological Samples Collection Project and Investigational REgistry for the On-going Study of Disease Origin, Progression and Treatment (Intermountain INSPIRE Registry)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02450006
• Other study ID #: 1024811
• Status: Recruiting
• Start date: April 2015
• Est. completion date: April 2050

Study information

• Verified date: August 2022
• Source: Intermountain Health Care, Inc.
• Contact: Joseph B Muhlestein, MD
• Phone: 801-507-4701
• Email: brent.muhlestein[@]imail.org
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

To collect biological samples, clinical information and laboratory data from patients diagnosed with any healthcare-related conditions who are seen at facilities affiliated with Intermountain Healthcare, including patients and their family members, and to collect the same information and samples from a general population including disease-free subjects.

Description:

This is an observational, non-randomized, open, long-term project to collect a variety of biological samples, in addition to usual or specialized care clinical information and laboratory test results, from patients who present to Intermountain Healthcare-affiliated facilities, with symptoms of any healthcare-related conditions, as well as from a general population including disease-free subjects. The INSPIRE Registry will include all subjects enrolled in the HHD registry (IRB # 1007406, approval date 01- 16-2009) and the cathlab database registry (IRB # 1008366, approval date 10/04/2000), as of IRB approval date of this INSPIRE amended protocol. Since this is a registry database project, there are no investigational treatments, drugs or procedures associated with participation. Information obtained from this registry project will not have direct or immediate benefit for any of the participants. Biological samples and subject information will be obtained during diagnostic procedures and/or treatment that are generally part of usual or specialized care for the underlying healthcare-related condition. Sample testing and registry data utilization for various research projects can be initiated only after the appropriate approval is obtained from a registry oversight/management committee, and when appropriate, the Institutional Review Board. After informed consent is obtained from the patient, the biological samples will be obtained in one of the following ways: 1. During a procedure from access lines inserted for the procedure, or 2. When other ordered lab work is done, or 3. As a separate sample collection if no other lab work is planned. Biological sample collection from the general population may be a separate blood draw and/or sample collection. Participating patients may be asked to provide one or more collections of biological samples. Biological samples may be used in current and future research tests multiple times, or until the sample is consumed. In addition, participating subjects may be asked to complete the IRBreviewed questionnaires.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50000
• Est. completion date: April 2050
• Est. primary completion date: April 2050
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Males or females of any age, any ethnicity, diagnosed with any healthcare-related conditions, presenting to an Intermountain Healthcare-affiliated facility or males or females of any age, any ethnicity, with or without any healthcare-related conditions, including disease-free subjects, from a general population that may include unaffected family members
• Patient or patient's representative has the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures, using a form that is approved by the applicable IRB.

Exclusion Criteria:

• Inability or refusal of the patient and/or the patient's legally-acceptable representative to provide informed consent for any reason.
• Other conditions that in the opinion of the Principal Investigator or Co-Investigator(s) may increase risk to the subject and/or compromise the quality of the registry project.

Related Conditions & MeSH terms

• Condition

Locations

Country	Name	City	State
United States	Intermountain Medical Center and Intermountain Clinics	Murray	Utah

Sponsors (1)

Lead Sponsor	Collaborator
Intermountain Health Care, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	All-cause mortality		10 years